Evidence map›Paper›PMID 33392223›Full record

ArticleFrontiers in medicine2020

Dabigatran Level Before Reversal Can Predict Hemostatic Effectiveness of Idarucizumab in a Real-World Setting.

Nicolas Gendron, Richard Chocron, Paul Billoir, Julien Brunier, Laurence Camoin-Jau, Marie Tuffigo, Dorothée Faille, Dorian Teissandier, Juliette Gay, Emmanuelle de Raucourt and 15 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
1.9field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 11 institutions in 2 countries.

Nicolas GendronUniversité de Paris, Innovative Therapies in Haemostasis, INSERM, Paris, France.
Richard ChocronUniversité de Paris, PARCC, INSERM, Paris, France.
Paul BilloirNormandie Univ, UNIROUEN, INSERM Rouen University Hospital, Vascular Hemostasis Unit, Rouen, France.
Julien BrunierCHU-Pellegrin, Laboratory of Hematology, Bordeaux, France.
Laurence Camoin-JauAP-HM, CHU Timone, Laboratory of Hematology, Marseille, France.
Marie TuffigoCHU Angers, Laboratory of Hematology, Angers, France.
Dorothée FailleUniversité de Paris, Laboratory of Vascular Translational Science, INSERM, Paris, France.
Dorian TeissandierCHU Clermont-Ferrand, Emergency Medicine Department, Clermont-Ferrand, France.
Juliette GayUniversité de Paris, Innovative Therapies in Haemostasis, INSERM, Paris, France.
Emmanuelle de RaucourtUniversité de Paris, LVTS, INSERM, Paris, France.
Ludovic SunerSorbonne Université, Inserm, Centre de Recherche Saint-Antoine, AP-HP, Hôpital Saint-Antoine, Hématologie Biologique, Paris, France.
Corentin BonnetCHU Sud Réunion, Anaestesiology Department, Saint-Pierre, La Réunion, France.
Anne-Céline MartinUniversité de Paris, Innovative Therapies in Haemostasis, INSERM, Paris, France.
Dominique LasneAP-HP, CHU Necker-Enfants Malades, Department of Biogical Hematology, Paris, France.
Chayma LadhariCHU Montpellier, Centre Régional de Pharmacovigilance, Montpellier, France.
Aurélien LebretonCHU Clermont-Ferrand, Laboratory of Hematology, Clermont-Ferrand, France.
Laurent BertolettiService de Médecine Vasculaire et Thérapeutique, CHU de Saint-Étienne, INSERM, Université Jean-Monnet, INSERM, CHU de Saint-Étienne, Saint-Étienne, France.
Nadine AjzenbergUniversité de Paris, Laboratory of Vascular Translational Science, INSERM, Paris, France.
Pascale GaussemUniversité de Paris, Innovative Therapies in Haemostasis, INSERM, Paris, France.
Pierre-Emmanuel MorangeAP-HM, CHU Timone, Laboratory of Hematology, Marseille, France.
Véronique Le Cam DuchezNormandie Univ, UNIROUEN, INSERM Rouen University Hospital, Vascular Hemostasis Unit, Rouen, France.
Alain ViallonCHU Saint-Étienne, Emergency Department, Saint-Étienne, France.
Pierre-Marie RoyF-CRIN INNOVTE, Saint-Étienne, France.
Agnès Lillo-le LouëtUniversité de Paris, Innovative Therapies in Haemostasis, INSERM, Paris, France.
David M SmadjaUniversité de Paris, Innovative Therapies in Haemostasis, INSERM, Paris, France.
Inserm · FRCentre Hospitalier Universitaire d'Angers · FRCentre Hospitalier Universitaire de Clermont-Ferrand · FRCentre Hospitalier Universitaire de La Réunion · FRCentre Hospitalier Universitaire de Saint-Étienne · FRCentre Occitanie-Montpellier · FRHôpital Necker-Enfants Malades · FRHôpital Pellegrin · FRMéditerranée Infection Foundation · FRUnité de Nutrition Humaine · FRUniversité Claude Bernard Lyon 1 · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

bleedingdabigatranhemostatic effectivenessidarucizumabperioperativereboundreversal

Identifiers

PMID33392223
PMCPMC7772865
OpenAlexW3111301901

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.